Podcast Episodes

Back to Search
Episode 102: Voices from the coronavirus pandemic, in Italy, New York, and the high seas
Episode 102: Voices from the coronavirus pandemic, in Italy, New York, and the high seas

How long will this pandemic persist? Are U.S. hospitals going to be overwhelmed? And what’s it like to be quarantined on a cruise ship?

6 years, 7 months ago

Short Long
View Episode
Episode 101: Pharma’s response to coronavirus, Google's appetite for health data, & biotech in China
Episode 101: Pharma’s response to coronavirus, Google's appetite for health data, & biotech in China

Does “The Art of the Deal” cover vaccines? Is patient privacy a relic of the past? And how big can biotech get in China?

6 years, 7 months ago

Short Long
View Episode
Episode 100: Wall Street's coronavirus freakout, clinical trial difficulties, and a look back
Episode 100: Wall Street's coronavirus freakout, clinical trial difficulties, and a look back

Is the market overreacting to the coronavirus? Why do so many clinical trials go unfilled? And how do you pronounce "Martin Shkreli"?

6 years, 7 months ago

Short Long
View Episode
Episode 99: Genetic medicine w/ Ethan Weiss, drug industry infighting, & a microbiome review
Episode 99: Genetic medicine w/ Ethan Weiss, drug industry infighting, & a microbiome review

Can biopharma police itself? Who decides whether something's a disease or a difference? And will fecal matter ever become a drug?

6 years, 8 months ago

Short Long
View Episode
Episode 98: Les Funtleyder on biotech investing; the Zolgensma lottery & billionaire philanthropy
Episode 98: Les Funtleyder on biotech investing; the Zolgensma lottery & billionaire philanthropy

What's the right way to give drugs away? Is $3 billion even a lot of money? And when is biotech hype justified?

6 years, 8 months ago

Short Long
View Episode
Episode 97: Fake outbreak news, treating coronavirus, and biotech's Mount Rushmore
Episode 97: Fake outbreak news, treating coronavirus, and biotech's Mount Rushmore

Is peer review underrated? Can biotech stop an outbreak? And would you mind giving us a call? We're coming up on the 100th episode of this podcast, a…

6 years, 8 months ago

Short Long
View Episode
Episode 96: A chemist breaks bad, the latest on the coronavirus, and pharma’s slow Bern
Episode 96: A chemist breaks bad, the latest on the coronavirus, and pharma’s slow Bern

Is it wise to lie to the feds? Is pharma taking Sen. Bernie Sanders seriously? And what constitutes a "public health emergency of international conce…

6 years, 8 months ago

Short Long
View Episode
Episode 95: The latest on the China virus, Sarepta's ongoing FDA saga, and biotech at Davos
Episode 95: The latest on the China virus, Sarepta's ongoing FDA saga, and biotech at Davos

Are we dealing with a SARS redux? Has the FDA lost its teeth? And what do billionaires talk to each other about?

6 years, 8 months ago

Short Long
View Episode
Episode 94: EQRx's Alexis Borisy, Stephen Buck on his website for cancer patients, and a JPM recap
Episode 94: EQRx's Alexis Borisy, Stephen Buck on his website for cancer patients, and a JPM recap

Why weren't there any big deals announced this week? What does the word "equivalar" mean? And why is information about prognosis so hard to find?

6 years, 9 months ago

Short Long
View Episode
Episode 93: Josiah Zayner on getting canceled, good news in cancer, an Ebola vaccine saga
Episode 93: Josiah Zayner on getting canceled, good news in cancer, an Ebola vaccine saga

Does pharma deserve more credit? Will history forgive He Jiankui? And how does a laboratory eureka become a lifesaving vaccine?

6 years, 9 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us